Avoro Capital Advisors Reduces $5M in uniQure N.V. ($QURE)
Key Points
- Avoro Capital Advisors changed its uniQure N.V. ($QURE) stake by 3.1% last quarter, cutting to 5,959,595 shares worth $164.31 million.
- Wall Street's consensus rating on $QURE is Buy and an average price target of $38.96.
- $QURE last traded around $27.57.
Avoro Capital Advisors trimmed its position in uniQure N.V. ($QURE) by 3.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,959,595 shares of uniQure N.V. after selling 190,405 shares during the quarter. Avoro Capital Advisors's holdings in uniQure N.V. were worth $164.31 million as of its most recent filing.
uniQure N.V. ($QURE) Stock
uniQure N.V. Earnings
Analysts Set New Price Targets
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.